title: Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma.
abstract: The efficacy and toxicity of neoadjuvant carboplatin and paclitaxel administered on a weekly schedule for locally advanced cervical carcinoma were evaluated. Thirty patients staged as IB2-IVA according to the FIGO were treated with carboplatin (AUC 2; an area under the time-concentration of 2 mg*min/ml based on creatinine clearance) and paclitaxel (60 mg/m(2)) intravenously, every week for six cycles. A type III radical hysterectomy was then undertaken. Thirty patients were enrolled in this study. An objective response was recorded in 26 patients (87%, 95% CI 70-95%). Progressive disease was not observed. Grade 3 neutropenia was observed in only two patients (7%), and grade 1 or 2 neuropathy was seen in six patients (20%). The combination of carboplatin and paclitaxel given in weekly schedule for advanced cervical carcinoma was highly active, permitting a high rate of subsequent surgical resectability. It was well tolerated. This regimen may provide improved outcomes with minimal toxicity.
authors.affiliation: Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Hosokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Honjo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D016190:Carboplatin; D017239:Paclitaxel